Bronwen E Shaw, MD, PhD

Professor; Scientific Director CIBMTR

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MD - Doctor of Medicine
PhD

Biography

Dr. Shaw received her MD (MBChB) from the University of Cape Town, South Africa in 1993. All of her subsequent postgraduate haematology specialist training was completed in London, UK where she also received her PhD in Clinical Sciences and Immunology from University College London in 2004. Her PhD was entitled Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors.

Research Interests

Prior to taking up her position at the CIBMTR and MCW, Dr. Shaw was a Consultant Haematologist specializing in Stem Cell Transplantation and Survivorship issues at the Royal Marsden Hospital in Sutton, UK. She simultaneously held the position of Chief Medical Officer at Anthony Nolan, the UK’s national unrelated donor registry. In this position she had oversight of the donor research activities and the medical operations of the organization. She also held a senior scientific role, with direct supervision of several PhD and MD students working in the area of immunogenetics, donor selection, and the donor experience.

Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy.

(Kelly DL, Syrjala K, Taylor M, Rentscher KE, Hashmi S, Wood WA, Jim H, Barata A, Flynn KE, Burns LJ, Shaw BE, Petersdorf E, Yero AC, Emmrich AD, Morris KE, Costanzo ES, Knight JM.) Transplant Cell Ther. 2021 09;27(9):747-757 PMID: 34139388 PMCID: PMC8428782 SCOPUS ID: 2-s2.0-85110419978 06/18/2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

(Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM.) Transplant Cell Ther. 2021 Aug 27 PMID: 34461278 08/31/2021
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation.

(Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, Shaw BE, Shaw P, Spellman SR, Marsh SGE.) J Clin Oncol. 2021 Jul 20;39(21):2397-2409 PMID: 33835855 PMCID: PMC8280068 SCOPUS ID: 2-s2.0-85112125420 04/10/2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.

(Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J.) J Clin Oncol. 2021 Jun 20;39(18):1971-1982 PMID: 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 04/28/2021
The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic.

(Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, Wingard JR.) Transplant Cell Ther. 2021 06;27(6):507-516 PMID: 33865804 PMCID: PMC8217124 SCOPUS ID: 2-s2.0-85108052714 04/19/2021
Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.

(Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, Shaw BE, Stroncek DF.) Transplant Cell Ther. 2021 06;27(6):503.e1-503.e8 PMID: 33823169 PMCID: PMC8217152 SCOPUS ID: 2-s2.0-85103924669 04/07/2021
Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.

(Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, Shaw BE.) JCO Clin Cancer Inform. 2021 05;5:494-507 PMID: 33950708 PMCID: PMC8443829 SCOPUS ID: 2-s2.0-85105478562 05/06/2021
Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study.

(Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA.) Transplant Cell Ther. 2021 04;27(4):352.e1-352.e5 PMID: 33836890 PMCID: PMC8036235 SCOPUS ID: 2-s2.0-85101149566 04/11/2021
Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation.

(Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT, Worldwide Network for Blood & Marrow Transplantation.) Transplant Cell Ther. 2021 03;27(3):270.e1-270.e6 PMID: 33781537 PMCID: PMC7834678 03/31/2021
Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study

(Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, Shaw BE, Pulsipher MA.) Transplantation and Cellular Therapy. April 2021;27(4):352.e1-352.e5 SCOPUS ID: 2-s2.0-85101149566 04/01/2021
Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation

(Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT.) Transplantation and Cellular Therapy. March 2021;27(3):270.e1-270.e6 SCOPUS ID: 2-s2.0-85101114408 03/01/2021
Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program

(El Fakih R, Greinix H, Koh M, Shaw B, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja MA, Perales MA, Savani BN, Majhail NS, Passweg JR, Sureda A, Ahmed SO, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen KK, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi SK, Horowitz MM, Weisdorf D, Niederwieser D, Aljurf M.) Transplantation and Cellular Therapy. March 2021;27(3):267.e1-267.e5 SCOPUS ID: 2-s2.0-85101137848 03/01/2021